Interventional News’ top 10 most popular items of September 2022

2022

TOP 10Interventional News’ most popular content last month included news of the acquisition of a new catheter by Bentley, the announcement of the final patient enrolled in a liquid embolic study, latest data from the SAVAL trial of a drug-eluting stent, and a video discussion of the current landscape of deep vein thrombosis (DVT) treatment.

1) Bentley acquires GoBack catheter from Upstream Peripheral Medical Technologies

 

2) Medtronic receives CE mark for first balloon-expandable covered stent for ChEVAR

Medtronic announced that it has recently received CE mark for its Radiant balloon-expandable covered stent, the first and currently, only, covered stent indicated for use in chimney endovascular aneurysm repair (ChEVAR) with the Endurant II/IIs stent graft system.

 

3) Stryker receives FDA clearance for OptaBlate system

Stryker has announced in a press release that its OptaBlate bone tumour ablation system (OptaBlate) has received 510(k) clearance from the US Food and Drug Administration (FDA). The addition of the OptaBlate technology to Stryker’s Interventional Spine (IVS) portfolio expands on its core competencies in vertebral augmentation and radiofrequency ablation and completes its portfolio of treatment options for metastatic vertebral body fractures.

 

4) VIDEO: Why ClotTriever is a “gamechanger” for the treatment of deep vein thrombosis

Andrew Wigham (Oxford, UK) and Rick De Graaf (Friedrichshafen, Germany) discuss the current state of DVT treatment at the Leipzig Interventional Course (LINC) 2022 (6–9 June, Leipzig, Germany), with both noting that “a massive problem” in Europe is the lack of awareness around treatment.

 

5) New liquid embolic multicentre trial successfully enrols final patient

Fluidx Medical announces completion of trial enrolment for its GPX embolic device. In this multicentre trial, GPX was used to treat a variety of primary and metastatic tumours, renal adenoma tumours, and a range of other arterial and venous applications.

 

6) SAVAL trial finds no gains with drug-eluting stents in PAD below the knee

Day one of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting (10–14 September, Barcelona, Spain) put a strong focus on peripheral arterial disease (PAD). At a [email protected] session, Hans van Overhagen (Haga Teaching Hospital, Den Haag, The Netherlands), as European principal investigator, presented the primary results of the SAVAL trial.

 

7) Philips gives updates on spectral detector angio CT solution

Philips announced new milestones in the development of the world’s first spectral detector angio computed tomography (CT) solution— Philips Spectral Angio CT suite—bringing the company’s breakthrough spectral CT imaging technology into an integrated hybrid angio CT suite.

 

8) Penumbra and Asahi Intecc partner to introduce Indigo System to Japan

Penumbra and Asahi Intecc, a Japanese medical device manufacturer, announced that they will collaborate to introduce Penumbra’s Indigo Aspiration System into the Japanese market upon regulatory approval.

 

9) “Interventional oncology must become reliable and reproducible”

Reto Bale (Medizinische Universität Innsbruck, Innsbruck, Austria) gave a presentation titled ‘Stereotactic thermal ablation—can it break the current limits?’ at the 2022 European Conference of Interventional Oncology (ECIO; 24–27 April, Vienna, Austria). A key takeaway was that the stereotactic procedure yields “excellent” results.

 

10) Advertorial: Quality Ablation: Treating challenging lesions with increased accuracy and speed

Ablation is used to destroy or shrink tumours in the liver, lung, kidney, bone, and other organs. In recent decades, image-guided ablation has become integral to modern cancer therapy with curative or palliative intent. Although a promising treatment option, the main challenge is the accurate and safe positioning of the ablation probes to achieve complete tumour coverage, especially in difficult-to-access localisations.


LEAVE A REPLY

Please enter your comment!
Please enter your name here